Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. Juni 2020 08:00 ET | Quelle: Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals Announces Full Enrollment in its Ongoing Phase 2B Trial of Tc99m Tilmanocept in Rheumatoid Arthritis (RA)

DUBLIN, OH, June 15, 2020 (GLOBE NEWSWIRE) -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic...
09. Juni 2020 07:30 ET | Quelle: Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals to Present at the Virtual Investor Fireside Chat Series

Live Video Moderated Discussion with CEO, Jed Latkin, to be Held on Tuesday, June 16th, at 2:00 PM ET, Immediately Followed by an Interactive Q&A Session DUBLIN, Ohio, June 09, 2020 (GLOBE...
03. Juni 2020 07:30 ET | Quelle: Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the European League Against Rheumatism (EULAR) Congress

DUBLIN, Ohio, June 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of...